Although post-glucose challenge suppression of glucagon is reduced in people with type 2 diabetes [56], upregulation of glucagon and inhibition of SRH-induced appetite may be one of the mechanisms of tirzepatide’s action in reducing body weight. The gene discussed is GCG; the disease is type 2 diabetes mellitus.